{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:10:03Z","timestamp":1793322603609,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200424"],"award-info":[{"award-number":["82200424"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015401","name":"Shaanxi Province Key Research and Development Projects","doi-asserted-by":"publisher","award":["2022SF-078"],"award-info":[{"award-number":["2022SF-078"]}],"id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.lfs.2025.124083","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T02:44:34Z","timestamp":1762829074000},"page":"124083","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Dapagliflozin attenuates post-infarction fibrosis via cardiomyocyte protection and fibroblast inhibition"],"prefix":"10.1016","volume":"383","author":[{"given":"Min","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guantong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Botao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linwan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dengfeng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2025.124083_bb0005","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.038644","article-title":"Heart disease mortality in the United States, 1970 to 2022","volume":"14","author":"King","year":"2025","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.lfs.2025.124083_bb0010","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00395-020-00829-5","article-title":"Mouse models of atherosclerosis and their suitability for the study of myocardial infarction","volume":"115","author":"Golforoush","year":"2020","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.lfs.2025.124083_bb0015","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.amjmed.2005.08.010","article-title":"Management of post-myocardial infarction patients with left ventricular systolic dysfunction","volume":"120","author":"Gheorghiade","year":"2007","journal-title":"Am. J. Med."},{"key":"10.1016\/j.lfs.2025.124083_bb0020","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1016\/j.jacc.2021.01.060","article-title":"Braunwald, E, thrombolysis in myocardial infarction (TIMI) study group: JACC focus seminar 2\/8","volume":"77","author":"Sabatine","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.lfs.2025.124083_bb0025","article-title":"Deficiency of the RNA-binding protein RBMS1 improves myocardial fibrosis and heart failure","author":"Li","year":"2025","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.lfs.2025.124083_bb0030","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1186\/s40001-025-02834-7","article-title":"Impact of SGLT2 inhibitors on myocardial fibrosis in diabetic HFpEF: a longitudinal study","volume":"30","author":"Albulushi","year":"2025","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.lfs.2025.124083_bb0035","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1038\/s41467-025-56703-2","article-title":"CD248-targeted BBIR-T cell therapy against late-activated fibroblasts in cardiac repair after myocardial infarction","volume":"16","author":"Chen","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lfs.2025.124083_bb0040","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jacc.2018.11.053","article-title":"Sigusch, H, PCI and CABG for treating stable coronary artery disease: JACC review topic of the week","volume":"73","author":"Doenst","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2022","key":"10.1016\/j.lfs.2025.124083_bb0045","first-page":"e895","article-title":"AHA\/ACC\/HFSA guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.lfs.2025.124083_bb0050","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2025.124083_bb0055","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.119.042929","article-title":"Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial","volume":"140","author":"Nassif","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.lfs.2025.124083_bb0060","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","article-title":"Effect of Dapagliflozin on heart failure and mortality in type 2 diabetes mellitus","volume":"139","author":"Kato","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.lfs.2025.124083_bb0065","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1161\/CIRCULATIONAHA.123.065390","article-title":"Piezo1-mediated neurogenic inflammatory Cascade exacerbates ventricular remodeling after myocardial infarction","volume":"149","author":"Sun","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.lfs.2025.124083_bb0070","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1007\/s11010-024-05112-y","article-title":"Myeloid-derived suppressor cells alleviate adverse ventricular remodeling after acute myocardial infarction","volume":"480","author":"Wang","year":"2025","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.lfs.2025.124083_bb0075","article-title":"Isolation of cardiomyocytes from fixed hearts for immunocytochemistry and ploidy analysis","volume":"164","author":"Y\u00fccel","year":"2020","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.lfs.2025.124083_bb0080","article-title":"Promotion of cardiac microtissue assembly within G-CSF-enriched collagen I-cardiogel hybrid hydrogel, Regen","volume":"11","author":"Khodayari","year":"2024","journal-title":"Biomater"},{"key":"10.1016\/j.lfs.2025.124083_bb0085","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12933-020-01066-9","article-title":"Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia\/reperfusion injury","volume":"19","author":"Lahnwong","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.lfs.2025.124083_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116994","article-title":"SGLT2 inhibitor Dapagliflozin alleviates cardiac dysfunction and fibrosis after myocardial infarction by activating PXR and promoting angiogenesis","volume":"177","author":"Wang","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.lfs.2025.124083_bb0095","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1007\/s40618-023-02162-9","article-title":"The anti-inflammatory and immunological properties of SGLT-2 inhibitors","volume":"46","author":"Bendotti","year":"2023","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.lfs.2025.124083_bb0100","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bcp.2018.03.013","article-title":"Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells","volume":"152","author":"Xu","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.lfs.2025.124083_bb0105","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1186\/s12933-024-02481-y","article-title":"Dapagliflozin mitigates cellular stress and inflammation through PI3K\/AKT pathway modulation in cardiomyocytes, aortic endothelial cells, and stem cell-derived \u03b2 cells","volume":"23","author":"Alsereidi","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.lfs.2025.124083_bb0110","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s12933-024-02369-x","article-title":"Effect of extracellular matrix stiffness on efficacy of Dapagliflozin for diabetic cardiomyopathy","volume":"23","author":"Zhu","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.lfs.2025.124083_bb0115","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.3390\/ijms24044004","article-title":"Fibrosis: types, effects, markers, mechanisms for disease progression, and its relation with oxidative stress, immunity, and inflammation","volume":"24","author":"Antar","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2025.124083_bb0120","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41392-024-01840-1","article-title":"Liu, C, macrophages in cardiovascular diseases: molecular mechanisms and therapeutic targets","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.lfs.2025.124083_bb0125","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1093\/eurheartj\/ehac223","article-title":"Bauersachs, J, left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies","volume":"43","author":"Frantz","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.lfs.2025.124083_bb0130","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jacc.2024.10.103","article-title":"Myocardial fibroblast activation after acute myocardial infarction: a positron emission tomography and magnetic resonance study","volume":"85","author":"Barton","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.lfs.2025.124083_bb0135","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2025.124083_bb0140","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/s12916-022-02485-z","article-title":"Dapagliflozin attenuates diabetes-induced diastolic dysfunction and cardiac fibrosis by regulating SGK1 signaling","volume":"20","author":"Lee","year":"2022","journal-title":"BMC Med."},{"key":"10.1016\/j.lfs.2025.124083_bb0145","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12933-021-01312-8","article-title":"Dapagliflozin: a sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGF\u03b21\/Smad signaling","volume":"20","author":"Zhang","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.lfs.2025.124083_bb0150","first-page":"26","article-title":"GSTM1 suppresses cardiac fibrosis post-myocardial infarction through inhibiting lipid peroxidation and ferroptosis","volume":"12","author":"Chen","year":"2025","journal-title":"Mil. Med. Res."},{"key":"10.1016\/j.lfs.2025.124083_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174715","article-title":"Shafiei, M, Dapagliflozin exerts anti-inflammatory effects via inhibition of LPS-induced TLR-4 overexpression and NF-\u03baB activation in human endothelial cells and differentiated macrophages","volume":"918","author":"Abdollahi","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.lfs.2025.124083_bb0160","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/s12276-022-00800-5","article-title":"Cardiac-specific overexpression of Ndufs1 ameliorates cardiac dysfunction after myocardial infarction by alleviating mitochondrial dysfunction and apoptosis","volume":"54","author":"Qi","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.lfs.2025.124083_bb0165","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/eurjpc\/zwaa147","article-title":"Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017","volume":"28","author":"Bragazzi","year":"2021","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.lfs.2025.124083_bb0170","doi-asserted-by":"crossref","DOI":"10.4028\/b-7TThNX","article-title":"Inflammation-targeted nanomedicines alleviate oxidative stress and reprogram macrophages polarization for myocardial infarction treatment","volume":"11","author":"Hu","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.lfs.2025.124083_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2020.153405","article-title":"Nootkatone attenuates myocardial oxidative damage, inflammation, and apoptosis in isoproterenol-induced myocardial infarction in rats","volume":"84","author":"Meeran","year":"2021","journal-title":"Phytomedicine"},{"key":"10.1016\/j.lfs.2025.124083_bb0180","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41586-020-2797-4","article-title":"Cells of the adult human heart","volume":"588","author":"Litvi\u0148ukov\u00e1","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2025.124083_bb0185","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jconrel.2021.05.023","article-title":"Biotherapeutic-loaded injectable hydrogels as a synergistic strategy to support myocardial repair after myocardial infarction","volume":"335","author":"Zheng","year":"2021","journal-title":"J. Control. Release"}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320525007192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320525007192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T16:13:35Z","timestamp":1766074415000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320525007192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":37,"alternative-id":["S0024320525007192"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2025.124083","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dapagliflozin attenuates post-infarction fibrosis via cardiomyocyte protection and fibroblast inhibition","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2025.124083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"124083"}}